(Q34332586)

1 August 2017

1 reference

title

Risk factors and incidence of posttransplant diabetes mellitus (English)

1 reference

1 August 2017

Reisaeter AV

1

1 reference

1 August 2017

Hartmann A

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

Transplantation Proceedings

1 August 2017

1 reference

1 August 2017

33

1 reference

1 August 2017

5A Suppl

1 reference

1 August 2017

8S-18S

1 reference

Some Characteristics of Steroid Diabetes: A Study in Renal-Transplant Recipients Receiving High-Dose Corticosteroid Therapy

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Posttransplant diabetes in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Risk for posttransplant Diabetes mellitus with current immunosuppressive medications

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Tacrolimus (FK506) as primary immunosuppressant after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Optimization of the immunosuppressive protocol after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Post-transplant diabetes mellitus. The role of immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

Post-transplant diabetes mellitus in renal allograft recipients: a matched-pair control study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902229-1

7 January 2021

10.1016/S0041-1345(01)02229-1

Identifiers

DOI

1 reference

release_kc7kaoe2zzg53kmzypyd54a23i

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kc7kaoe2zzg53kmzypyd54a23i

24 November 2022

mapped directly with Wikidata item

1 reference